The small-molecule inhibitor of CPSF3, JTE-607, has been shown to be effective in killing acute myeloid leukemia and Ewing’s sarcoma cells and inhibit breast cancer cell migration and invasion.16,49 Our work extends these findings by demonstrating that JTE-607 inhibits the growth of hormone-sensitive and -insensitive prostate cancer cells, as well as benign prostate epithelial cells. Here, CPSF3 is linked to prostate carcinoma.